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Abstract: Antithrombotics have been shown to decrease the risk of stroke in patients with atrial 
ﬁ  brillation (AF). However they are associated with an increased risk of bleeding. We assessed 
the frequency and appropriateness of antithrombotic therapy in patients admitted to our service 
with stroke and AF. A retrospective case study of 219 patients (mean age 77.2 years) admitted 
between January 1999 and 31 December 2001 with a diagnosis of stroke and AF was done. Patient 
characteristics, presence of comorbid conditions, knowledge of preadmission AF, medication 
history and appropriateness of antithrombotic treatment were recorded. One hundred and ﬁ  fty 
patients were known to have had AF prior to admission. Forty-one presented with an intracranial 
hemorrhage (19 on warfarin, 10 on aspirin). Of those patients with known AF only 43 were 
on treatment consistent with the guidelines. Warfarin was recommended in 144 of the whole 
cohort, but only 39 were taking it. Fifty-three patients were receiving aspirin although warfarin 
was the recommended treatment. Fifty-four with known AF were not on any antithrombotic 
treatment. Factors signiﬁ  cantly associated with the use of antithrombotic treatment were history 
of AF (p = 0.0004), valvular heart disease (p = 0.02), venous thromboembolism (p = 0.04), risk 
of thromboembolism (p = 0.003) and presentation with a nonischemic infarct (p = 0.008).
Antithrombotic therapy use in our patients differs signiﬁ  cantly from guideline recommendations. 
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Introduction
Atrial ﬁ  brillation (AF) is associated with an increased risk of stroke (Atrial 
Fibrillation Investigators 1994). The risk is increased in patients who have had a 
previous stroke or transient ischemic attack (TIA), are hypertensive, have conges-
tive cardiac failure, diabetes or are older than 65 years (Laupacis et al 1998; Gage 
et al 2001). A number of studies have shown that antithrombotic therapy with 
either warfarin or aspirin is successful in reducing the risk of stroke (Petersen et al 
1989; Stroke Prevention in Atrial Fibrillation Investigators 1991; Atrial Fibrillation 
Investigators 1994; Hart et al 1999; Lip and Boos 2006). Most comparative studies 
favor warfarin, but major bleeding events are usually more frequent with warfarin 
(Morocutti et al 1997; Hart and Halperin 1999; Taylor et al 2001). However it 
should be noted that a recent report from DiMarco and colleagues (2005) has shown 
similar bleeding risks with either warfarin or aspirin. Warfarin is recommended as 
ﬁ  rst line treatment (unless contraindicated) followed by aspirin in patients with AF 
who are at high risk of stroke (Laupacis et al 1998; Hart and Halperin 1999). Yet 
the uptake of warfarin is not as great as one would predict from population studies 
largely because it is perceived as carrying a high risk of bleeding, requires ongo-
ing monitoring and the elderly (who are most likely to beneﬁ  t from warfarin) have 
other risk factors such as increased risk of falls or dementia that place them at risk Therapeutics and Clinical Risk Management 2007:3(3) 492
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of bleeding complications (Sudlow et al 1998; Bungard 
et al 2000; Go et al 2003; Laguna et al 2004). Furthermore, 
in clinical trials anticoagulation is carefully monitored in 
highly motivated patients, such accuracy might be difﬁ  cult 
to achieve in clinical practice. 
The subtype of stroke is a further factor to consider 
when deciding on which agent to employ in at risk patients. 
Not all ischemic strokes that occur in patients with AF are 
cardioembolic. It has been estimated that one third of strokes 
occurring in patients are due to small vessel disease or have 
an atherosclerotic basis (Evans et al 2000; Hart et al 2000). 
In these patients antiplatelet therapy may be preferred as 
there is no difference in mortality or stroke recurrence 
whether these patients are treated with warfarin or aspirin 
(Evans et al 2001). In addition it is well known that there is 
a higher prevalence of AF in older individuals and increasing 
age is also associated with an increased prevalence of small 
vessel disease (Atrial Fibrillation Investigators 1994). With 
an increasing aging population these are necessary factors 
to consider before commencing therapy. In this study we 
assessed the frequency and appropriateness of antithrom-
botic therapy in patients who were admitted to our service 
with stroke and AF. We decided to include patients who had 
either ischemic or hemorrhagic strokes as this represents true 
clinical practice. Unlike the randomized clinical trials, we did 
not exclude patients in whom warfarin (for example venous 
thromboembolic disease or valvular heart disease) or aspirin 
(ischemic heart disease) was clearly indicated. 
Methods
The study was a retrospective case study of patients who 
were admitted to Capital and Coast District Health Board 
hospitals with a diagnosis of stroke with documented AF 
on admission. The sample was recruited by identifying all 
adult admissions between 1 January 1999 to 31 December 
2001 with a primary or secondary diagnosis of any form 
of an intracranial vascular event using the relevant ICD-10 
codes, these being I600–I679 or G450–G468 (International 
Statistical Classiﬁ  cation of Diseases 2000). Each record was 
examined and patients were included if the admission met 
the WHO deﬁ  nition for cerebrovascular accident (CVA) or 
TIA (Hatano 1976). There also had to be ECG evidence of 
AF. In addition we extracted the following information from 
the case record: the basic demographic details, presence of 
co-morbid conditions, history of the presentation including 
the occurrence of preadmission AF, medication history on ad-
mission, initial examination ﬁ  ndings, functional assessment 
using the Barthel score (Tennant et al 1996) within the ﬁ  rst 
week after admission. Where it was not available the inves-
tigators derived a functional grade. This was completed from 
the patients’ functional level as documented in the case notes 
from physiotherapy, occupational therapy and nursing assess-
ments. Functional grades of low, medium, high and normal 
were assessed to correspond to a Barthel score of 0–4, 5–9, 
10–19 and 20 respectively. Where available transthoracic 
echocardiographic ﬁ  ndings were noted. 
Radiological classiﬁ  cation 
All CT scans and/or MRI imaging was independently 
reviewed by an investigator (MN) who was provided with a 
précis of the relevant clinical features of the presentation. The 
investigator was blinded to the original radiological report 
and the antithrombotic treatment status of the patient. The 
CT scans were classiﬁ  ed initially as to whether there was 
intraparenchymal or extra-axial hemorrhage. Thereafter the 
lesions were coded according to a modiﬁ  ed TOAST classiﬁ  -
cation using a 2 cm cut point (for subcortical and brainstem) 
instead of 1.5 cm to permit the use of the Miller subtype 
scheme (Adams Jr et al 1993; Miller et al 1993). 
Subtype of ischemic stroke
The classiﬁ  cation of the subtype of ischemic stroke was based 
on the methodology of Miller and colleagues (1993), but was 
modiﬁ  ed as angiography was only very rarely performed 
in our hospitals. The patients were classiﬁ  ed into one of 
the following six groups: cardioembolic (deﬁ  nite), cardio-
embolic (probable), lacunar, atherothrombotic, ischemic 
(miscellaneous) or ischemic (uncertain). Two investigators 
(CB and TI) independently placed each stroke into one of 
the above categories. If there was a difference of opinion, 
the particular case was discussed and a consensus agreement 
was reached. 
Questionnaire
A questionnaire was sent to the primary care physician of 
each patient requesting information on whether the diagnosis 
of AF was known prior to the admission and if so whether 
the patient was on treatment for the same. If not a reason 
for not using either agent was requested. We also requested 
information on the preadmission functional status of the 
patient, prior history of a CVA or TIA or both and history 
of the relevant comorbidity. 
Guideline recommended therapy
Each patient was assigned a guideline recommended 
therapy of ‘warfarin’, ‘aspirin’ or ‘either,’ according to the Therapeutics and Clinical Risk Management 2007:3(3) 493
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recommendations of Laupacis et al 1998. This is based on 
categorization of age (<65 years, 65–75 years, >75 years) 
and the presence or absence of additional risk factors for 
stroke (TIA, systemic embolus or stroke, hypertension, poor 
left ventricular function, rheumatic mitral valve disease or 
prosthetic heart valve). These guidelines, published in 1998, 
were available prior to the start of the study period and hence 
represent best practice at the time. These guidelines are very 
similar to the CHADS2 Index (Gage et al 2001) that is now 
more frequently used to assess stroke risk. They differ in the 
age criterion – >75 years in the CHADS2 index and an addi-
tional point for patients who have had a previous stroke or TIA. 
As 144 of our patients were 75 years or older it is unlikely that 
the stroke risks score would have changed signiﬁ  cantly. 
Statistical methods
Simple univariate measures of association and t-tests were 
used to test the association between potential risk factors 
for the use versus nonuse of any antithrombotic (aspirin or 
warfarin), and warfarin use versus aspirin or no antithrom-
botic therapy.
Logistic regression, using a variety of model selection 
procedures (backwards selection, and stepwise selection), 
was used to try and establish independent risk factors for 
antithrombotic use. 
Two derived variables were used in the model building 
process. One was a variable that counted up the number of 
risk factors for bleeding (a history of prior bleeding, peptic 
ulcer disease, cognitive impairment, hepatic disease, alcohol 
abuse and the risk of falling), with possible scores between 0 
and 6. The other was a variable that counted up the number 
of risk factors for stroke in the presence of AF (hypertension, 
diabetes mellitus, a history of prior stroke or TIA, congestive 
heart failure and age over 65 years), with possible scores 
between 0 and 5. The technique appropriate to ordinal 
variables, the Wilcoxon test, was also used for these derived 
variables. Log-normally distributed continuous data (INR) 
are presented as geometric means with geometric conﬁ  dence 
intervals and t-tests. SAS version 8.2 (SAS Institute, Cary 
NC, 2001) was used for the analysis. 
The project was approved by the Wellington Regional 
Ethics Committee.
Results
During the period of the audit 2090 patients were identiﬁ  ed 
from discharge coding. Of these 219 met the criteria for the 
study (Figure 1). One hundred and ﬁ  fty of these were known 
to have had AF prior to admission. 
The characteristics of the patients are shown in Table 1. 
The mean age of our patients was 77.2 years, 144 of whom 
were 75 years or older. The risk factors for stroke or bleeding 
are also shown in Table 1. The mean stroke risk score per 
individual was 2.19, whereas the mean bleeding risk score 
was 0.43 per individual. 
Forty-one patients were diagnosed with an intracranial 
hemorrhage, 19 (46.3%) of these were taking warfarin and 
10 (24.4%) aspirin on admission. According to recommended 
guidelines all bar one of these patients would have been 
recommended to have warfarin (Laupacis et al 1998). There 
were no differences in the INR levels between patients with 
hemorrhagic strokes or ischemic infarcts (geometric mean 
INR 1.90 and 2.06 respectively, p = 0.57).
The subtypes of stroke are shown in Table 2. One 
hundred and forty three of 177 ischemic events (80.8%) were 
categorized as either deﬁ  nite or probable cardioembolic with 
the rest being lacunar or ischemic (uncertain). Seventy-one 
of the 143 patients with a deﬁ  nite or possible cardioembolic 
stroke were on an antithrombotic agent (warfarin, 17 pa-
tients (11.9%) or aspirin, 54 patients (37.8%)). Twelve of 
the 23 patients with lacunar strokes were on either warfarin 
(4 patients, 17.4%) or aspirin (8 patients, 34.8%). 
Table 3 shows the actual and recommended treatments for 
the whole cohort and for those whose AF had been diagnosed 
prior to the present admission. 
Of the 150 patients with known AF, only 43 (28.7%) 
were on treatment consistent with the guidelines. In 144 of 
the 219 patients warfarin was the recommended agent, yet 
only 39 patients (27.1%) were taking it. A further 53 patients 
(36.8%) for whom warfarin was recommended were receiv-
ing aspirin. Among all those patients with known AF, 54 
patients (36%) were not on any antithrombotic treatment. 
For the whole cohort a similar percentage (42%) was not 
taking any antithrombotic treatment.
The factors associated with a greater or lesser likelihood 
of using antithrombotic treatment are shown in Table 4. In 
addition patients who had had a previous CVA or TIA or 
had a history of ischemic heart disease were more likely to 
be using some form of antithrombotic treatment. Factors 
that were associated with warfarin use were a history of 
venous thromboembolism, a history of AF prior to admis-
sion, nonischemic (hemorrhagic stroke syndrome) and older 
age (Table 5). 
Sixty-seven patients had an echocardiogram performed. 
The mean (SD) left ventricular ejection fraction was 
56.9 (13.8)%; left atrial size 46.6 (10.8 mm) and fractional 
shortening was 31.2 (8.7)%. Left atrial size was signiﬁ  cantly Therapeutics and Clinical Risk Management 2007:3(3) 494
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n = 121
Notes unavailable
n = 13
Age outside range
n = 1
Admission outside study period
n = 62
Duplicate admission (transfer)
n = 404
No neurological event meeting definition
n = 247
No ECG present
n = 1023
NoAF on ECG
n = 219
AF on ECG
n = 1242
ECG present
n = 1489
Neurological event meeting WHO definition for TIA or CVA
n = 1893
Admission not a duplicate
n = 1955
Admission between 1/1/1999–31/12/2001
n = 1956
Age >15
n = 1969
Notes available for examination
n = 2090
Cases identified from discharge coding
Figure 1 Inclusion criteria ﬂ  ow chart.Therapeutics and Clinical Risk Management 2007:3(3) 495
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larger among those on antithrombotic agents compared with 
those not on any antithrombotics (49.9 mm versus 43.6 mm 
respectively, p = 0.01). No signiﬁ  cant differences were 
observed between LV ejection fraction (p = 0.97) or fractional 
shortening (p = 0.74).
A bleeding history and a history of peptic ulcer disease 
were associated with a decreased use of any antithrombotic 
history (p = 0.04).
Discussion
Our study has shown in an unselected group of patients 
admitted with a stroke syndrome and AF that antithrombotic 
treatments with either anticoagulants or antiplatelet agents 
are underused according to contemporary recommendations 
(Petersen et al 1989; Atrial Fibrillation Investigators 1994; 
Stroke Prevention in Atrial Fibrillation (SPAF) Investigators 
1991; EAFT Study Group 1993; Laupacis et al 1998; Go et al 
2003; Hylek et al 2003; Gage et al 2004; Perez-Gomez et al 
2004). Under use was particularly marked with warfarin 
where only 43 patients (19.6%) were taking the drug prior to 
admission. According to the guidelines available at the time 
of the study it would have been indicated in 144 patients. 
Low uptake has previously been described in the primary 
care setting where Sudlow and colleagues (1998), noted that 
only 23% of patients with AF were using anticoagulants. Two 
more recent studies from the USA (Go et al 2003; Wang et al 
2003) showed differing uptake of anticoagulation after AF 
was diagnosed. Go and colleagues (2003) noted that nearly 
55% of their cohort with nonvalvular AF and in whom there 
was no contraindication to warfarin were prescribed this 
drug whereas Wang et al 2003 noted in a community based 
survey that 705 of 861 patients with AF were not treated with 
warfarin, however it is not clear from this study how many of 
the patients had contraindications to anticoagulation. Wang 
and colleagues (2003) point out that using their risk score, 
stroke rates in patients with low scores (45% of their cohort) 
were of the order of 1.1 to 1.5 strokes per 100 person years 
which would suggest that this may be near the threshold for 
the use of anticoagulants. Our patients seem to have had more 
severe disease than those of Wang and colleagues (2003) 
as most of them had co-morbidities that would have placed 
them in a moderate to high-risk stroke group. 
Overall, the uptake of warfarin in patients with nonvalvu-
lar AF has remained a problem despite adequate publicity of 
its effectiveness with quoted prescription rates of 15%–44% 
(Bungard et al 2000; Iqbal et al 2005). The reasons provided 
for not using warfarin by the primary care physicians in 
our study were similar to those enunciated by Bungard and 
colleagues (2000), in that they included past history of bleed-
ing, noncompliance, cognitive difﬁ  culties, frailty and patient 
choice. Although not mentioned by our practitioners we think 
that lack of a monitoring centre for anticoagulation probably 
also played a role in the nonprescription of this drug. Use of 
warfarin is time consuming for a general practitioner and we 
think this may have proved a barrier for our prescribers.
Even where anticoagulants are prescribed there might be 
signiﬁ  cant drop out rate. Evans and colleagues (2000), noted 
in a sample of 288 patients that 74 stopped taking warfarin, 25 
because of bleeding complications and 37 for reasons such as 
choice, compliance or logistics. Similar ﬁ  ndings were reported 
from the much larger AFFIRM Study where 33.6% of the trial 
participants discontinued warfarin use for some period during 
the trial. The major reason for withdrawal was maintenance of 
Table 1 Patient characteristics
  No. of Patients (%)
Demographics  
Gender:  Male: Female  89:130  (40.6):(59.4)
Age:  Mean (±SD)  77.2 years  ±11.9
Age:  Median (Range)  79.6 years  (31–96 years)
Ethnicity:  European  177  (82.7)
Smoker:  Current or ex-smoker  80  (36.5)
Risk factors for stroke   
Age >65 years  187  (85.4)
Prior stroke or TIA  91  (41.6)
Congestive heart failure  55  (25.1)
Hypertension 107  (48.9)
Diabetes mellitus  35  (16.0)
Stroke Risk Score (mean ± SD)  2.19  ±1.09
Risk factors for bleeding   
Prior bleeding  12  (5.5)
Peptic ulcer disease  17  (7.8)
Cognitive impairment  33  (15.1)
Hepatic disease  1  (0.5)
Alcohol abuse  7  (3.2)
Documented risk of falling  24  (11.0)
Bleeding Risk Score (mean ± SD)  0.43  ±0.69
Table 2 Stroke details
Variable  No. of Patients (%)
Characteristics of stroke   
Ischemic stroke  177  (80.8)
Nonischemic 41  (18.7)
Nonvascular 1  (0.5)
Ischemic stroke subtype (% of Ischemic)
Cardioembolic-deﬁ  nite  104  (58.8)
Cardioembolic-probable 39  (22.0)
Lacunar 23  (13.0)
Atherothrombotic 0  (0.0)
Ischemic uncertain  11  (6.2)Therapeutics and Clinical Risk Management 2007:3(3) 496
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sinus rhythm, but bleeding was the second most common reason 
for stopping warfarin (DiMarco et al 2005). 
Efforts suggested to improve the use and compliance 
with warfarin have included home follow-up following 
initiation of warfarin in hospital. Jackson and colleagues 
(2004) compared usual care (namely, managed totally by 
the general practitioner) with a project pharmacist who 
visited patients at home and adjusted the dose of warfarin 
accordingly. Using this programme the pharmacist arm of the 
study achieved a signiﬁ  cantly greater proportion of patients 
with a therapeutic INR early in treatment with less bleeding 
events as well. A pharmacist led programme is attractive 
because they are familiar with drug interactions and the dif-
ﬁ  culties with using warfarin. They are also likely to maintain 
the INR in the therapeutic range. This will decrease the risk 
of bleeding and also decrease the risk of stroke as patients 
who are under anticoagulated have a similar risk of stroke 
as those who are treated with placebo. Funding for such an 
arrangement might prove difﬁ  cult in New Zealand where it 
would have to come from the local District Health Board. If 
this were not forthcoming it would be difﬁ  cult to see where 
the salaries for the pharmacists would be found.
Other options to make warfarin use more attractive relate 
to self-monitoring of the INR in a similar fashion as diabetics 
monitor blood glucose. Two recent studies have shown 
markedly different outcomes. Gardiner and colleagues (2004) 
showed that self-testing in 84 patients from an anticoagulation 
clinic was effective and acceptable. However the trial was open 
and not controlled. It involved 84 patients who were self se-
lected from 800 who were invited to take part. The average age 
of the trialists was less than the average age of other patients in 
the anticoagulation clinic. The second study reported by Mur-
ray and colleagues (2004) was a randomized controlled trial 
involving 608 (of 2586 invited) patients. Three hundred and 
twenty seven patients were randomized to self-management, 
but of these 26% were unable to complete training. Factors that 
were associated with success in training and continuing in the 
trial were younger age and more education. The authors point 
out that 76% of the original cohort chose not to undertake self 
testing and their recommendations were that standardization 
and dissemination of training would be needed with adequate 
backup from clinicians if this method was to be successful. 
In summary some form of central control of anticoagulation 
seems to be the best method to increase the use of warfarin. 
Our study also demonstrated potential problems with 
the use of antithrombotics. Forty-one of our 219 patients 
(18.7%) presented with hemorrhage. Nineteen of these 
Table 3 Antithrombotic treatment versus guideline recommended therapy
Actual treatment  Guideline recommendations a 
 Warfarin  Warfarin  OR  Aspirin  Aspirin  Neither  Total
All subjects (n = 219)
All Subjects 
Warfarin AND Aspirin  3  0  0  0  3
Warfarin 39  1  0  0  40
Aspirin 71  3  1  0  75
Neither 91  4  6  0  101
Total 204  8  7  0  219
Subjects with known atrial ﬁ  brillation (n = 150)        
Subjects with known AF   
Warfarin AND Aspirin  2  0  0  0  2
Warfarin 37  1  0  0 38
Aspirin 53  2  1  0  56
Neither 52  0  2  0  54
Total 144  3  3  0  150
aNotes: Based on the guidelines presented by Laupacis et al 1998.
Table 4 Factors associated with the use or nonuse of 
antithrombotic drugsa
Variable  Odds ratios (95% CI)b p  value
History of AF  3.4  (1.74–6.65)  0.0004
History of valvular   15.1  (1.62–141.1)  0.02
heart disease
History of venous   4.2  (1.07–16.4)  0.04
thrombo-embolism
Risk of   0.68  (0.44–1.05)  0.08
bleeding scorec
Risk of thrombo-  1.58  (1.16–2.13)  0.003
embolism scorec
Ischemic infarctd 0.32  (0.14–0.74)  0.008
Notes: aMultivariate model; bOdds ratio >1, more likely to be using any antithro-
botic; cper increase in one risk factor; dDuring index admission.Therapeutics and Clinical Risk Management 2007:3(3) 497
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were extra-axial (9 patients were taking warfarin, 4 aspirin 
and 6 neither), the rest were intracerebral (10 patients on 
warfarin, 5 on aspirin and 6 neither). Although one cannot 
be sure that the drugs were responsible for the hemorrhage 
they do seem to be over represented. These ﬁ  ndings are of 
importance and conﬁ  rm the results of others who have noted 
that warfarin is associated with a signiﬁ  cantly increased risk 
of bleeding when compared to aspirin or placebo (Taylor 
et al 2001; Go et al 2003; DiMarco et al 2005). This risk 
needs to be balanced against the risk of stroke in patients 
with nonvalvular AF. 
Although the potential beneﬁ  ts of warfarin therapy in 
high-risk populations have been clearly demonstrated (Lip 
and Boos 2006) the decision to prescribe any agent has to be 
balanced against the risk (or “perceived risks”) from therapy. 
These risks are often difﬁ  cult to quantify in the individual 
patient and older patients who are likely to gain most beneﬁ  t 
are often considered to be at higher risk. Our data suggests 
that often where warfarin therapy was recommended aspirin 
was substituted. Aspirin is signiﬁ  cantly easier to prescribe 
as it does not require blood test monitoring, is used in a 
ﬁ  xed dose and is considered safer than warfarin in reqard to 
bleeding complications, despite bleeding risks with either 
treatment being small (Koudstaal 2000). Furthermore, a 
signiﬁ  cant percentage (28.3%) of our patients may have been 
on aspirin for ischemic heart disease (IHD), in such patients 
aspirin would be indicated and our prescribers may not have 
wished to add warfarin to aspirin for fear of an increased 
bleeding risk. Yet, as mentioned earlier warfarin is superior 
to aspirin in preventing stroke in patients with AF.
Investigators have assessed a combination of warfarin and 
aspirin using a subtherapeutic INR of 1.5–1.9. Such trials have 
not proved successful in preventing stroke in patients with AF 
(SPAF III Investigators 1996; Gullov et al 1998; Edvardson 
et al 2003). A more recent study compared a combination 
of triﬁ  lusal (a cyclooxygenase inhibitor) and therapeutic 
warfarin against therapeutic warfarin in high-risk patients 
with AF and in a second group compared triﬁ  lusal alone 
versus a combination of triﬁ  lusal and warfarin (INR tritrated 
to 1.25 to 2) in patients with an intermediate risk of stroke 
(Perez-Gomez et al 2004). The results showed added beneﬁ  t 
in stroke prevention with the combinations with no increase 
in bleeding risk, but the patients were very closely monitored 
and the median INR in the intermediate group was 1.93 and 
2.17 in the high-risk group respectively. The result particularly 
with the intermediate risk group would suggest that the INR 
should be at a level near to 2 to gain any beneﬁ  t. Therefore 
this might be an option when using warfarin particularly in 
intermediate risk patients. We had a small number of patients 
with lacunar infarcts, this may represent the assessment sys-
tem that we used, but the placement in this group depended 
on the clinical picture and the CT scan report. Approximately 
50% of these patients were on some form of antithrombotic 
treatment. Of the 12 patients, 8 were taking aspirin and 4 
warfarin. Aspirin may be the preferred agent in these patients 
as it is equally effective and is safer than warfarin (Evans et al 
2001). Although aspirin is recommended in patients with 
either contraindications to warfarin or small vessel disease 
it should be noted that for many of our patients this was the 
ﬁ  rst presentation of cerebrovascular disease and thus without 
prior imaging it would potentially be difﬁ  cult to know which 
patients would be suitable for aspirin. 
In conclusion, we have shown that in patients presenting 
to hospital with stroke syndromes and atrial ﬁ  brillation, anti-
thrombotic treatment is underused and differs signiﬁ  cantly from 
guidelines. We have suggested changes to correct practice that 
should make warfarin more frequently used. We believe an 
anticoagulation service with signiﬁ  cant pharmacist input would 
offer the best solution. 
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